

**Appendix I of the letter from Drs. Olivieri and Gallie
to Dr. Michael Baker 9 April 2019**

Specific Questions for Clinical Inquiry

- Were there violations of the standard of care in the prescribing of unlicensed deferiprone for patients in the Thalassemia Program?
- Were there violations of other standards of care (outside that of prescribing unlicensed deferiprone, e.g., monitoring) for patients in the Thalassemia Program?
- Have patients in the Thalassemia Program been informed of any risks or harms that they have suffered or may suffer in the future as a result of the prescribing of unlicensed deferiprone or lack of appropriate monitoring in the Thalassemia Program?
- Should Health Canada be notified about any adverse events associated with the use of deferiprone (if ever delivered through the SAP program)?
- How and why were international experts in thalassemia removed from thalassemia patient care in 2009?
- How and why were other individuals who lack Canadian training and fellowships placed in positions of authority over thalassemia patients?
- Does the Thalassemia Program have the requisite competent leadership and staff to deliver safe and effective care to its patients?
- What are the remedial steps (e.g., education) that are required to ensure that all clinicians in the Thalassemia Program are competent with respect to the use of deferiprone?
- What clinical practice policies and procedures are required to ensure that patients in the Thalassemia Program receive the appropriate drugs and monitoring?